LT3290052T - Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2 - Google Patents

Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2

Info

Publication number
LT3290052T
LT3290052T LTEP17191118.3T LT17191118T LT3290052T LT 3290052 T LT3290052 T LT 3290052T LT 17191118 T LT17191118 T LT 17191118T LT 3290052 T LT3290052 T LT 3290052T
Authority
LT
Lithuania
Prior art keywords
growth factor
monoclonal antibodies
factor receptor
fibroblast growth
fibroblast
Prior art date
Application number
LTEP17191118.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Kim KYUNG JIN
Wei-Meng Zhao
Hangil Park
Original Assignee
Galaxy Biotech, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech, Llc filed Critical Galaxy Biotech, Llc
Publication of LT3290052T publication Critical patent/LT3290052T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEP17191118.3T 2008-11-07 2009-11-06 Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2 LT3290052T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US16487009P 2009-03-30 2009-03-30

Publications (1)

Publication Number Publication Date
LT3290052T true LT3290052T (lt) 2020-02-25

Family

ID=42153600

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17191118.3T LT3290052T (lt) 2008-11-07 2009-11-06 Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2
LTEP14188785.1T LT2842573T (lt) 2008-11-07 2009-11-06 Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP14188785.1T LT2842573T (lt) 2008-11-07 2009-11-06 Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2

Country Status (20)

Country Link
US (8) US8101723B2 (enExample)
EP (4) EP3783024A1 (enExample)
JP (8) JP5627591B2 (enExample)
KR (1) KR101699432B1 (enExample)
CN (1) CN102131524B (enExample)
AU (1) AU2009313357B2 (enExample)
BR (1) BRPI0917315B8 (enExample)
CA (2) CA3166399A1 (enExample)
DK (3) DK2365828T3 (enExample)
ES (3) ES2646168T3 (enExample)
HR (2) HRP20171640T1 (enExample)
HU (1) HUE035700T2 (enExample)
LT (2) LT3290052T (enExample)
MX (1) MX2011000455A (enExample)
NO (1) NO2842573T3 (enExample)
PL (3) PL2842573T3 (enExample)
PT (3) PT3290052T (enExample)
RU (1) RU2546254C9 (enExample)
SI (2) SI3290052T1 (enExample)
WO (1) WO2010054265A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021841A2 (en) * 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
PT3290052T (pt) 2008-11-07 2020-02-06 Galaxy Biotech Llc Anticorpos monoclonais para o recetor 2 do fator de crescimento de fibroblastos
PH12012502215A1 (en) * 2010-05-11 2017-08-23 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
SG11201403085PA (en) * 2011-12-14 2014-10-30 Seattle Genetics Inc Fgfr antibody drug conjugates (adcs) and the use thereof
AU2013229488B2 (en) 2012-03-08 2017-12-07 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
MX360851B (es) * 2012-04-09 2018-11-16 Daiichi Sankyo Co Ltd Anticuerpo anti-fgfr2.
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
HRP20190157T1 (hr) * 2012-12-21 2019-03-22 Janssen Biotech, Inc. Senzitivni višestruki imunotest za topljive receptore faktora rasta fibroblasta
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
SI3027651T1 (sl) * 2013-08-01 2019-05-31 Five Prime Therapeutics, Inc. Afukozilirana protitelesa proti fgfr2iiib
KR20220019839A (ko) * 2013-10-08 2022-02-17 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
CN103757026B (zh) 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
WO2016163433A1 (ja) * 2015-04-08 2016-10-13 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
JPWO2016171107A1 (ja) * 2015-04-20 2018-03-22 第一三共株式会社 Ｆｇｆｒ２の検出
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
IL291926B2 (en) 2015-11-23 2024-06-01 Five Prime Therapeutics Inc FGFR2 inhibitors alone or in combination with immunostimulating agents in cancer treatment
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
KR20250010107A (ko) 2017-05-16 2025-01-20 파이브 프라임 테라퓨틱스, 인크. 암 치료에서 화학요법제와 병용되는 항-fgfr2 항체
US11603401B2 (en) 2017-06-02 2023-03-14 Ablynx N.V. Aggrecan binding immunoglobulins
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
JP7548587B2 (ja) 2018-09-07 2024-09-10 アイタブメッド （エイチケイ） リミテッド 二重特異性抗原結合タンパク質及びその使用
CA3112215A1 (en) 2018-10-05 2020-04-09 Five Prime Therapeutics, Inc. Anti-fgfr2 antibody formulations
MX2022007961A (es) * 2019-12-24 2022-07-12 Dizal Jiangsu Pharmaceutical Co Ltd Nuevos anticuerpos anti-fgfr2b.
JP7686000B2 (ja) * 2019-12-24 2025-05-30 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
JP2023528454A (ja) * 2020-06-03 2023-07-04 ザ・ブロード・インスティテュート・インコーポレイテッド 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
CN116847876A (zh) * 2020-12-29 2023-10-03 深圳福沃药业有限公司 抗fgfr2抗体及其用途
CN118103401A (zh) * 2021-10-08 2024-05-28 深圳福沃药业有限公司 Adcc增强型抗fgfr2抗体及其用途
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
CN120418288A (zh) * 2022-09-30 2025-08-01 思康睿奇(上海)药业有限公司 FGFR2b抗体及其用途
TW202442685A (zh) * 2023-04-28 2024-11-01 大陸商武漢人福創新藥物研發中心有限公司 抗FGFR2b單抗
AU2024277592A1 (en) * 2023-05-19 2025-11-20 Sunshine Lake Pharma Co., Ltd. Anti-fgfr2 antibody and use thereof
CN119855835A (zh) * 2023-06-13 2025-04-18 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
TW202527998A (zh) * 2023-12-18 2025-07-16 大陸商山東先聲生物製藥有限公司 抗FGFR2b抗體-藥物綴合物及其應用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) * 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
EP0723556A4 (en) * 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
KR20090125840A (ko) * 2001-06-13 2009-12-07 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간 모노클로날 항체
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
DE60336452D1 (de) 2002-01-31 2011-05-05 Max Planck Gesellschaft Fgfr agoniste
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP1648998B1 (en) 2003-07-18 2014-10-01 Amgen Inc. Specific binding agents to hepatocyte growth factor
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7872016B2 (en) * 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
CA2648021A1 (en) 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US8945572B2 (en) * 2006-05-12 2015-02-03 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
ES2378097T3 (es) 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
JP5570218B2 (ja) * 2006-11-03 2014-08-13 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆｒ４抗体
ES2600882T3 (es) * 2007-03-23 2017-02-13 The Translational Genomics Research Institute Procedimiento de clasificación del cáncer de endometrio
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
PT3290052T (pt) 2008-11-07 2020-02-06 Galaxy Biotech Llc Anticorpos monoclonais para o recetor 2 do fator de crescimento de fibroblastos
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
PL2365828T3 (pl) 2015-04-30
JP5627591B2 (ja) 2014-11-19
EP3290052A1 (en) 2018-03-07
AU2009313357B2 (en) 2015-06-11
EP3290052B1 (en) 2019-12-25
JP6661734B2 (ja) 2020-03-11
PT2365828E (pt) 2014-12-12
US9834609B2 (en) 2017-12-05
US10689448B2 (en) 2020-06-23
EP2365828B1 (en) 2014-10-15
US10138301B2 (en) 2018-11-27
US9382324B2 (en) 2016-07-05
US20160362496A1 (en) 2016-12-15
CA2733668A1 (en) 2010-05-14
HUE035700T2 (en) 2018-05-28
NO2842573T3 (enExample) 2018-02-24
US20200347141A1 (en) 2020-11-05
US20230242650A1 (en) 2023-08-03
US20100196364A1 (en) 2010-08-05
EP2365828A2 (en) 2011-09-21
EP2842573B1 (en) 2017-09-27
CA3166399A1 (en) 2010-05-14
PT3290052T (pt) 2020-02-06
RU2546254C2 (ru) 2015-04-10
BRPI0917315A2 (pt) 2015-11-17
ES2770134T3 (es) 2020-06-30
JP2017019807A (ja) 2017-01-26
US20190153105A1 (en) 2019-05-23
DK3290052T3 (da) 2020-02-03
DK2365828T3 (en) 2014-12-08
EP2842573A1 (en) 2015-03-04
JP2014240385A (ja) 2014-12-25
AU2009313357A1 (en) 2010-05-14
HK1160012A1 (en) 2012-08-10
JP6960485B2 (ja) 2021-11-05
CA2733668C (en) 2022-08-30
JP2020096615A (ja) 2020-06-25
SI2842573T1 (en) 2018-01-31
EP2365828A4 (en) 2012-06-06
BRPI0917315B1 (pt) 2020-12-08
US20180094063A1 (en) 2018-04-05
US8101723B2 (en) 2012-01-24
CN102131524A (zh) 2011-07-20
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
PL3290052T3 (pl) 2020-06-29
JP2012508184A (ja) 2012-04-05
JP6342223B2 (ja) 2018-06-13
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
BRPI0917315B8 (pt) 2021-05-25
JP2019052165A (ja) 2019-04-04
DK2842573T3 (en) 2017-10-30
JP2022008996A (ja) 2022-01-14
JP2025032085A (ja) 2025-03-11
HRP20200090T1 (hr) 2020-04-03
US20140193899A1 (en) 2014-07-10
JP6445496B2 (ja) 2018-12-26
EP3783024A1 (en) 2021-02-24
JP2023116746A (ja) 2023-08-22
HK1207974A1 (en) 2016-02-19
CN102131524B (zh) 2014-05-14
KR101699432B1 (ko) 2017-01-24
US20120134994A1 (en) 2012-05-31
US8603987B2 (en) 2013-12-10
ES2523740T3 (es) 2014-12-01
KR20110081141A (ko) 2011-07-13
HK1249053A1 (en) 2018-10-26
WO2010054265A2 (en) 2010-05-14
PL2842573T3 (pl) 2018-04-30
LT2842573T (lt) 2017-12-11
HRP20171640T1 (hr) 2018-01-12
WO2010054265A3 (en) 2010-09-16
ES2646168T3 (es) 2017-12-12
JP7301106B2 (ja) 2023-06-30
SI3290052T1 (sl) 2020-07-31

Similar Documents

Publication Publication Date Title
HRP20171640T1 (hr) Monoklonska protutijela za receptor faktora rasta fibroblasta 2
IL199725A0 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
ZA201100301B (en) Recombinant anti-epidermal growth factor receptor antibody compositions
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
ZA200807903B (en) Humanized monoclonal antibodies to hepatocyte growth factor
EP2331579A4 (en) MONOCLONAL ANTIBODIES
ZA200906345B (en) Anti-sclerostin antibodies
PL2195026T3 (pl) Przeciwciała przeciw sklerostynie
SG10201601279SA (en) Monoclonal Antibody STRO-4
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
EP2125890A4 (en) ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
SI2483309T1 (sl) Protitelesa, ki se specifično vežejo na receptor epidermalnega rastnega faktorja
PL2121758T3 (pl) Ludzkie przeciwciała monoklonalne przeciwko receptorowi tyreotropiny, które działają jako antagoniści
ZA200905341B (en) Recombinant anti-epidermal growth factor receptor antibody compositions
TWI348915B (en) Anti-vegf monoclonal antibody
AU2006900785A0 (en) Antibodies to insulin-like growth factor I receptor